Everything on Biotech & Pharma

Viking Therapeutics' dual-mechanism weight loss data triggered a 36% stock surge, demonstrating the market's sensitivity to efficacy and durability in GLP-1 therapies. This has pressured incumbents like Novo Nordisk, whose stock fell to its lowest level since April.

Impact: Pharma investors should monitor clinical trial data for durability and multi-mechanism approaches, as these factors are now key drivers of valuation in the obesity treatment sector.

— from German Equity Adoption and AI Market Shifts · Alles auf Aktien – Die täglichen Finanzen-News· Sep 23, 2026